Launch the first AI-driven prostate cancer test
Not delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 24 Feb 2025
- Due
- 31 Dec 2025
- Checked
- 2 Oct 2026
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Myriad intends to commercially launch its first AI-driven prostate cancer test later in 2025”
What we found
Evidence strength A What the grades mean
The company did not launch the AI-driven prostate cancer test in 2025 as intended, with later filings indicating the launch was rescheduled for the second quarter of 2026.
-
A Myriad Genetics Inc. 8-K filed 2026-02-23
“full commercial launches of our AI-enabled Prolaris prostate cancer test in partnership with PATHOMIQ expected in the second quarter of 2026” ✓ confirmed on the page
-
A Myriad Genetics Inc. 8-K filed 2026-02-23
“The company continues to make progress and intends to commercially launch its first AI-enabled prostate cancer test, in partnership with PATHOMIQ, in the first half of 2026.” ✓ confirmed on the page
Market reaction: the shares moved +10.9% against the S&P 500 over the three sessions around the disclosure (20 Feb 2026 to 25 Feb 2026). What this measures
Checked 2 Oct 2026.
Commitment lineage
Every time the company restated this commitment. The original is never changed, and the outcome is always measured against version 1.
- Deadline drift +90 days
- 2 versions
-
Version 1 · original · stated 24 Feb 2025
Deadline 31 Dec 2025 (“later in 2025”) · wording aspirational
-
Version 2 · stated 5 Aug 2025
Deadline 31 Mar 2026 (“in the first quarter of 2026”) · wording aspirational
“intends to commercially launch its first AI-driven prostate cancer test, in partnership with PATHOMIQ, in the first quarter of 2026”
-
Version 3 · stated 5 May 2026
Deadline 30 Jun 2026 (“in the second quarter of 2026”) · wording expected
“expects to launch the test in the second quarter of 2026”
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Commercial launch
- Indicative materiality
- Medium rules
- Action
- Launch
- Deliverable
- AI-driven prostate cancer test
- Language
- Aspirational (“aims”, “intends”)
- In the company’s control
- High
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
- Third check on a negative finding: agreesBecause a negative finding could harm a company if wrong, a stronger model re-read the evidence fully blind and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Myriad Genetics Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2025-MYGN-003938 · Corrections policy